Deep Track reports small RAPT Therapeutics (RAPT) stake in Schedule 13G/A

Rhea-AI Filing Summary

RAPT Therapeutics, Inc. is the subject of an amended Schedule 13G filing in which Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin report beneficial ownership of 110,448 shares of common stock, representing 0.40% of the class as of December 31, 2025.

The reporting persons have shared voting and dispositive power over all 110,448 shares and no sole power. The percentage is based on 27,710,871 shares outstanding as of November 3, 2025, as disclosed in the issuer’s Form 10-Q. They certify the holdings are not for the purpose of changing or influencing control of RAPT.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 08:51 AM Learn about SEC filing dates

FAQ

What ownership stake does Deep Track report in RAPT (RAPT)?

Deep Track and related reporting persons disclose beneficial ownership of 110,448 RAPT common shares, equal to 0.40% of the class as of December 31, 2025. They hold shared voting and dispositive power over all these shares.

How was the 0.40% ownership in RAPT (RAPT) calculated?

The 0.40% ownership is based on 27,710,871 RAPT common shares outstanding as of November 3, 2025, according to the company’s Form 10-Q. Dividing Deep Track’s 110,448 shares by this total yields the disclosed percentage of the class.

Who are the reporting persons in this RAPT (RAPT) Schedule 13G/A?

The filing lists three reporting persons: Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. Each reports the same 110,448 RAPT common shares as beneficially owned, with shared voting and shared dispositive power.

Does Deep Track seek control of RAPT (RAPT) through this stake?

The reporting persons certify the RAPT shares were not acquired and are not held for the purpose of changing or influencing control of the issuer. They also state the holdings are not in connection with any transaction having that control-related purpose or effect.

What does ‘ownership of 5 percent or less’ mean for RAPT (RAPT)?

The filing states “Ownership of 5 percent or less of a class,” confirming the reported 0.40% RAPT stake is below the 5% threshold. This language indicates the holding is relatively small compared with the total common stock outstanding.

What powers do the reporting persons have over RAPT (RAPT) shares?

The reporting persons disclose no sole voting or dispositive power and shared voting and dispositive power over 110,448 shares of RAPT common stock. This means decisions to vote or sell these shares are made on a shared, rather than individual, basis.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

RAPT Therapeutics, Inc.

(Name of Issuer)

Common Stock $0.0001 par value per share

(Title of Class of Securities)

75382E208

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 75382E208

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 110,448.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 110,448.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

110,448.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.40 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 75382E208

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 110,448.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 110,448.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

110,448.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.40 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 75382E208

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 110,448.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 110,448.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

110,448.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.40 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: RAPT Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 561 Eccles Avenue, South San Francisco, California 94080
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Common Stock $0.0001 par value per share
(e)	CUSIP No.: 75382E208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 110,448
(b)	Percent of class: 0.40%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 110,448
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 110,448
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	02/13/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	02/13/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	02/13/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 27,710,871 Common Stock outstanding as of November 3, 2025, according to the issuer's Form 10-Q filed with the SEC on November 6, 2025 JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 13, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin